Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis.
Benoist ChibaudelMorteza RaeisiRomain CohenGreg YothersRichard M GoldbergJean-Baptiste BachetNorman WolmarkTakayuki YoshinoHans-Joachim E SchmollRachel KerrSara LonardiThomas J GeorgeEinat Shacham-ShmueliQian ShiThierry AndréAimery deGramontPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
No OS benefit of adjuvant OX was found in high-risk stage II CC, regardless of the definition used to characterize tumors as having a high risk for recurrence. Hence, our analysis suggests that OX should not be the standard of care for adjuvant chemotherapy for stage II CC, even in high-risk patients.